About: Lubeluzole

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Lubeluzole (Prosynap) is a drug which acts as an indirect NMDA antagonist. It inhibits the release of glutamate, inhibits nitric oxide synthesis, and blocks calcium and sodium gated ion channels. It has neuroprotective effects particularly in hypoxic conditions, and was developed for the treatment of stroke. Trials showed it to be safe, effective and well tolerated at low doses, but unfortunately higher doses produced the dangerous cardiac side effect of lengthening the QTc interval, which could potentially lead to heart failure, and so this meant that subsequent trials were limited to using only the low dose range. Animal studies had shown lubeluzole to produce neuroprotective effects when administered for prolonged periods, but the aim of its developers was to produce a drug that would b

Property	Value
dbo:abstract	Lubeluzole (Prosynap) is a drug which acts as an indirect NMDA antagonist. It inhibits the release of glutamate, inhibits nitric oxide synthesis, and blocks calcium and sodium gated ion channels. It has neuroprotective effects particularly in hypoxic conditions, and was developed for the treatment of stroke. Trials showed it to be safe, effective and well tolerated at low doses, but unfortunately higher doses produced the dangerous cardiac side effect of lengthening the QTc interval, which could potentially lead to heart failure, and so this meant that subsequent trials were limited to using only the low dose range. Animal studies had shown lubeluzole to produce neuroprotective effects when administered for prolonged periods, but the aim of its developers was to produce a drug that would be effective for preventing damage from acute stroke, and so ultimately it failed to show sufficient efficacy in trials and development for medical use was halted. (en)
dbo:casNumber	144665-07-6
dbo:chEMBL	281724
dbo:fdaUniiCode	V2SIB71583
dbo:kegg	D04789
dbo:pubchem	65998
dbo:thumbnail	wiki-commons:Special:FilePath/Lubeluzole.png?width=300
dbo:wikiPageID	18509688 (xsd:integer)
dbo:wikiPageLength	5725 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1084243048 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Fluoroarenes dbc:NMDA_receptor_antagonists dbc:Phenol_ethers dbc:Piperidines dbc:Secondary_alcohols dbr:Stroke dbr:Heart_failure dbr:Ion_channel dbr:Nitric_oxide dbr:Hypoxia_(medical) dbc:Benzothiazoles dbr:Long_QT_syndrome dbr:Neuroprotective dbr:Glutamate dbr:NMDA_antagonist
dbp:atcPrefix	none (en)
dbp:c	22 (xsd:integer)
dbp:casNumber	144665 (xsd:integer)
dbp:chembl	281724 (xsd:integer)
dbp:chemspiderid	59390 (xsd:integer)
dbp:f	2 (xsd:integer)
dbp:h	25 (xsd:integer)
dbp:iupacName	-1 (xsd:integer)
dbp:kegg	D04789 (en)
dbp:n	3 (xsd:integer)
dbp:o	2 (xsd:integer)
dbp:pubchem	65998 (xsd:integer)
dbp:s	1 (xsd:integer)
dbp:smiles	CNC3=NC4=CC=CC=C4S3 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	OZFSWVOEXHGDES-INIZCTEOSA-N (en)
dbp:unii	V2SIB71583 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	407754092 (xsd:integer)
dbp:width	280 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Glutamate_receptor_ligands
dcterms:subject	dbc:Fluoroarenes dbc:NMDA_receptor_antagonists dbc:Phenol_ethers dbc:Piperidines dbc:Secondary_alcohols dbc:Benzothiazoles
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Abstraction100002137 yago:Agent114778436 yago:Alcohol107884567 yago:Beverage107881800 yago:CausalAgent100007347 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:Element114840755 yago:Fluid114939900 yago:Food100021265 yago:Liquid114940386 yago:Matter100020827 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Substance100020090 yago:WikicatAlcohols yago:WikicatPhenolEthers umbel-rc:DrugProduct
rdfs:comment	Lubeluzole (Prosynap) is a drug which acts as an indirect NMDA antagonist. It inhibits the release of glutamate, inhibits nitric oxide synthesis, and blocks calcium and sodium gated ion channels. It has neuroprotective effects particularly in hypoxic conditions, and was developed for the treatment of stroke. Trials showed it to be safe, effective and well tolerated at low doses, but unfortunately higher doses produced the dangerous cardiac side effect of lengthening the QTc interval, which could potentially lead to heart failure, and so this meant that subsequent trials were limited to using only the low dose range. Animal studies had shown lubeluzole to produce neuroprotective effects when administered for prolonged periods, but the aim of its developers was to produce a drug that would b (en)
rdfs:label	Lubeluzole (en)
owl:sameAs	freebase:Lubeluzole yago-res:Lubeluzole wikidata:Lubeluzole dbpedia-sh:Lubeluzole dbpedia-sr:Lubeluzole https://global.dbpedia.org/id/4qttn
prov:wasDerivedFrom	wikipedia-en:Lubeluzole?oldid=1084243048&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Lubeluzole.png
foaf:isPrimaryTopicOf	wikipedia-en:Lubeluzole
is dbo:wikiPageRedirects of	dbr:Prosynap
is dbo:wikiPageWikiLink of	dbr:Prosynap dbr:Licostinel dbr:List_of_drugs:_Ls–Ly
is foaf:primaryTopic of	wikipedia-en:Lubeluzole